NasdaqCM:VKTXBiotechs
Is Early VANQUISH-1 Completion And VK2735 Progress Altering The Investment Case For Viking Therapeutics (VKTX)?
In November 2025, Viking Therapeutics reported that it had finished enrollment ahead of schedule in its Phase 3 VANQUISH-1 obesity trial, while also advancing its obesity candidate VK2735 into Phase 3 after earlier Phase 2 results.
At the same time, unusually large options activity and split bullish-bearish positioning by major traders highlighted how closely investors are watching Viking’s obesity program progress.
Next, we’ll examine how early completion of VANQUISH-1 enrollment shapes...